

## REFERENCES

- 21 USC § 812. [Schedules of controlled substances](#). 2012.
- Addiction Treatment Forum. [History of Buprenorphine](#). Addict Treat Forum Website. 2013.
- Al-Tayyib A, Rice E, Rhoades H, et al. [Association between prescription drug misuse and injection among runaway homeless youth](#). *Drug Alcohol Depend*. 2013;134:406-409.
- Alford DP, Compton P, Samet JH. [Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy](#). *Ann Intern Med*. 2006;144(2):127-134.
- Alford DP, Labelle CT, Kretsch N, et al. [Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience](#). *Arch Intern Med*. 2011;171(5):425-431.
- Alford DP, Labelle CT, Richardson JM, et al. [Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting](#). *Soc Gen Intern Med*. 2007;22:171-176.
- Alho H, Sinclair D, Vuori E, et al. [Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users](#). *Drug Alcohol Depend*. 2007;88(1):75-78.
- Alves Paula CG, Sales Célia MD, Ashworth Mark. [Personalising the evaluation of substance misuse treatment: a new approach to outcome measurement](#). *Int J Drug Policy*. 2015;26(4):333-335. doi:10.1016/j.drugpo.2014.11.014.
- Amass L, Ling W, Freese TE, et al. [Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience](#). *Am J Addict*. 2004;13:Suppl 1: S42-66.
- American Academy of Pediatrics. [Alcohol use by youth and adolescents: a pediatric concern](#). *Pediatrics*. 2010;125(5):1078-1087.
- American Psychiatric Association. [Diagnostic and statistical manual of mental disorders](#). Vol 5th edition. Washington, DC: Author; 2013.
- American Psychiatric Association. [Substance-Related and Addictive Disorders](#). APA. 2013.
- American Society of Addiction Medicine (ASAM). [Drug Testing As A Component Of Addiction Treatment and Monitoring Programs and in Other Clinical Settings](#). ASAM.org. 2010.
- American Society of Health-System Pharmacists. [Buprenorphine Injection: MedlinePlus Drug Information](#). April 2018.
- APA. [Focus on Marijuana: Current Risks and Controversies](#). Am Psychiatr Assoc Webinar. 2012.
- Arfken CL, Johanson CE, di Menza S, et al. [Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians](#). *J Subst Abuse Treat*. 2010;39(2):96-104.
- ASAM Board of Directors. [ASAM Public Policy Statement: Definition of Addiction](#). 2011.

- ASAM. [Advancing access to addiction medications](#). 2013.
- ASAM. [Summary of the Comprehensive Addiction and Recovery Act](#). 2016.
- ASAM. [The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use](#). June 2015.
- Association of State and Territorial Health Officials (ASTHO). [Neonatal Abstinence Syndrome: How States Can Help Advance the Knowledge Base for Primary Prevention and Best Practices of Care](#). 2014.
- Babor TF, Higgins-Biddle JC, Saunders JB, et al. [AUDIT: The Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care](#). Vol Second edition. World Health Organization, Department of Mental Health and Substance Dependence; 2001.
- Baca CT, Yahne CE. [Smoking cessation during substance abuse treatment: what you need to know](#). J Subst Abuse Treat. 2009;36(2):205-219.
- Back SE, Payne RL, Simpson AN. [Gender and prescription opioids: findings from the National Survey on Drug Use and Health](#). Addict Behav. 2010;35:1001-1007.
- Belbuca. [Belbuca HPC important safety information](#). www.belbuca.com. 2015.
- BioDelivery Sciences International. [Bunavail prescribing information](#). 2014.
- Birnbaum HG, White AG, Schiller M. [Societal costs of prescription opioid abuse, dependence, and misuse in the United States](#). Pain Med. 2011;4:657-667.
- Bliesener N, Albrecht S, Schwager A, et al. [Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence](#). J Clin Endocrinol Metab. 2005;90(1):203.
- Blow FC. [Special issues in treatment: old adults](#). In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol 3rd edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
- Blueshift Research. [Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market](#). Blueshift Research Report; 2017.
- BMJ. [Benzodiazepine overdose](#). 2017.
- Borg L, Kreek MJ. [The pharmacology of opioids](#). In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
- Brady KT, Myrick H, Sonne S. [Comorbid addiction and affective disorders](#). In: In: Graham AW, Schultz TK, Eds. Principles of Addiction Medicine. Vol Second Edition. Chevy Chase, Md: American Society of Addiction Medicine; 1998.
- Brands B, Blake J, Sproule B, et al. [Prescription opioid abuse in patients presenting for methadone maintenance treatment](#). Drug Alcohol Depend. 2004;73(2):199-207.
- Bray Jeremy W, Aden Brandon, Eggman Ashley A, et al. [Quality of life as an outcome of opioid use disorder treatment: A systematic review..](#) J Subst Abuse Treat. 2017;76:88-93. doi:10.1016/j.jsat.2017.01.019.
- Breen C. [There's a New Buprenorphine on the Block | Dr. Jeffrey Fudin](#). PainDr. February 2018.
- Brown RL, Leonard T, Saunders LA, et al. [The prevalence and detection of substance use disorder among inpatients ages 18 to 49: an opportunity for prevention](#). Prev Med. 1998;27:101-110.

- Bruce RD. [Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings](#). *Int J Drug Policy*. 2010;21:122-124.
- CADCA. [Comprehensive Addiction and Recovery Act \(CARA\)](#). CADCA.org. 2016.
- Casadonte PP. [PCSS Guidance: Buprenorphine Induction](#). Physician Clin Support Syst Website. 2009.
- CDC. [Opioid Data Analysis | Drug Overdose | CDC Injury Center](#). Cent Dis Control Prev. 2016.
- CDC. [Prescription Drug Overdose Data](#). 2015.
- CDC. [Understanding the epidemic](#). Cent Dis Control Prev Natl Cent Inj Prev Control Div Unintentional Inj Prev. 2017.
- CDC. [Vital Signs: Overdoses of prescription opioid pain relievers - United States, 1999-2008](#). *MMWR*. 2011;60(43):1487-1492.
- Center for Behavioral Health Statistics and Quality. [Key Substance Use and Mental Health Indicators in the United States: Results from the 2015 National Survey on Drug Use and Health](#). 2016.
- Chen MC, Beebe K. [A randomized trial of Probuphine implants in adults stabilized on sublingual buprenorphine](#). American Society of Addiction Medicine (ASAM) Annual Meeting. 2016.
- Chiang CN, Hawks RL. [Pharmacokinetics of the combination tablet of buprenorphine and naloxone](#). *Drug Alcohol Depend*. 2003;70(suppl 2):S39-S47.
- Chou R, Fanciullo GJ, Fine PG, et al. [Clinical guidelines for the use of chronic opioid therapy for chronic non-cancer pain](#). *J of Pain*. 2009;10(2):113-130.
- Chou Roger, Fanciullo Gilbert J, Fine Perry G, et al. [Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain](#). *J Pain Off J Am Pain Soc*. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008.
- Christo PJ, Manchikanti L, Ruan X, et al. [Urine Drug Testing In Chronic Pain](#). *Pain Physician*. 2011;14:123-143.
- Chychula NM, Sciamanna C. [Help substance abusers attain and sustain abstinence](#). *Nurse Pract*. 2002;27(11):30-47.
- Cicero JT, Dart RC, Inciardi JA, et al. [The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion, and Addiction-Related Surveillance \(RADARS\)](#). *Pain Med*. 2007;8(2):157-169.
- Cirone S. [Brief Intervention: Adolescent with Prescription Opioid Use Disorder](#). ; 2013.
- Clinical Tools, Inc. [Motivational Interviewing: Managing Challenging Patient Behavior - YouTube](#). September 2016.
- Conigliaro J, Reyes CD, Parran TV, et al. [Principles of screening and early intervention](#). In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. *Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
- Dahan A, Yassen A, Romberg R, et al. [Buprenorphine induces ceiling in respiratory depression but not in analgesia](#). *Br J Anaesth*. 2006;96(5):627-632.
- Daitch D, Daitch J, Novinson D, et al. [Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients](#). *Pain Med*. 2014;15(12):2087-2094.
- Darke S, Ross J. [Suicide among heroin users: rates, risk factors and methods](#). *Addiction*. 2002;97(11):1383-1394.
- Dart R. [Evaluation of ADFs Using RADARS System Data](#). 2011.

- Dart RC. Opioid Abuse, Misuse, and Diversion: Strategies for Prevention. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS). American Academy of Pain Medicine Meeting. 2009.
- Dasgupta N. [RADARS System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports](#). SAMHSA Meeting on Buprenorphine. 2010.
- Davis Karen, Schoenbaum Stephen C, Audet Anne-Marie. [A 2020 Vision of Patient-Centered Primary Care](#). J Gen Intern Med. 2005;20(10):953-957. doi:10.1111/j.1525-1497.2005.0178.x.
- Davis MP. [Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain](#). SupportiveOncology.net. 2012.
- De Vries TJ, Shippenberg TS. [Neural systems underlying opiate addiction](#). J Neurosci. 2002;22(9):3321-3325.
- Degenhardt L, Bucello C, Mathers B. [Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies](#). Addiction. 2011;106:32-51.
- Department of Veterans Affairs, Department of Defense. [VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Pocket Card](#). 2015.
- Donaher PA, Welsh C. [Managing opioid addiction with buprenorphine](#). Am Fam Physician. 2006;73(9):1573-1578.
- Dowell D, Haegerich TM, Chou R. [CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016](#). MMWR Recomm Rep. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
- Drug Abuse Warning Network (DAWN). [Highlights of the 2011 Drug Abuse Warning Network \(DAWN\) Findings on Drug-Related Emergency Department Visits](#). The Dawn Report; 2013:127.
- Drug Enforcement Administration (DEA). [Buprenorphine](#). 2013.
- Drug Enforcement Administration, Justice. [§ 1301.75 Physical security controls for practitioners](#). 2005.
- Drug Enforcement Administration. [Code of Federal Regulations: Section 1304.03 Maintenance of records and inventories](#). 2000.
- Drug Enforcement Administration. [State Prescription Drug Monitoring Programs](#). 2011.
- Drugs.com. [Buprenorphine/Naloxone](#). 2017.
- Drugs.com. [Doxazosin](#). Drugs.com. November 2015.
- Drugs.com. [Naloxone](#). Drugs.com. 2015.
- Dunn KE, Sigmon SC, Strain EC. [The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review](#). Drug Alcohol Depend. 2011;119(1-2):1-9.
- Dunn KM, Saunders KW, Rutter CM, et al. [Opioid prescriptions for chronic pain and overdose: a cohort study](#). Ann Intern Med. 2010;152(2):85-92.
- Durand F, Valla D. [Assessment of prognosis of cirrhosis](#). Clin Pharmacokinet. 2008;28(1):110-122.
- Edlund MJ, Martin BC, Russo JE, et al. [The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription](#). Clin J Pain. 2014;30(7):557-564.
- Egan JE, Casadonte P, Gartenmann T, et al. [The Physician Clinical Support System-Buprenorphine \(PCSS-B\): a novel project to expand/improve buprenorphine treatment](#). J Gen Intern Med. 2010;25(9):936-941.
- Eggleston W, Clark KH, Marraffa JM. [Loperamide abuse associated with cardiac dysrhythmia and death](#). Ann Emerg Med. 2016. doi:http://dx.doi.org/10.1016/j.annemergmed.2016.03.047.

- Emrick CD. [Alcoholics Anonymous and Other 12-Step Groups](#). *Textb Subst Abuse Treat*. 1999;403-411.
- Epstein Ronald M, Street Richard L. [The Values and Value of Patient-Centered Care](#). *Ann Fam Med*. 2011;9(2):100-103. doi:10.1370/afm.1239.
- Erdemoglu AK, Koc R. [Brief Pain Inventory score identifying and discriminating neuropathic and nociceptive pain](#). *Acta Neurol Scand*. 2013;128(5):351-358.
- Farmer Carrie M, Lindsay Dawn, Williams Jessica, et al. [Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process](#). *Subst Abuse*. 2015;36(2):209-216. doi:10.1080/08897077.2015.1012613.
- Farmer CM, Lindsay D, Williams J, et al. [Practice Guidelines for Burprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process](#). 2015;36(2).
- Farney RJ, McDonald AM, Boyle KM, et al. [Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone](#). *Eur Respir*. 2013;42:394-403.
- FDA Drug Safety Communication: [FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks](#). US Food Drug Adm Cent Drug Eval Res. September 2017.
- FDA. [CLIA - Clinical laboratory improvement amendments - currently waived analytes](#). 2016.
- FDA. [FDA approves first buprenorphine implant for treatment of opioid dependence](#). FDA News Events. May 2016.
- FDA. [FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder](#). November 2017.
- FDA. [FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults](#). 2018.
- FDA. [Medication Guide: Butrans™ CIII \(buprenorphine\) Transdermal System](#). 2010.
- FDA. [Medication Guide: Zubsolv Sublingual Tablet \(CIII\)](#). July 2013.
- FDA. [New, Safety Measures Announced for Extended-release and Long-acting Opioids](#). FDA Website. 2013.
- Fiellin D. [Treatment of acute pain in patients receiving buprenorphine/naloxone](#). March 2014.
- Fiellin DA, Rosenheck RA, Kosten TR. [Office-based treatment for opioid dependence: reaching new patient populations](#). *Am J Psychiatry*. 2001;158(8):1200-1204.
- Fiellin DA, Schottenfeld RS, Cutter CJ, et al. [Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial](#). *JAMA Intern Med*. 2014;174(12):1947-1954.
- Finch JW, Kamien JB, Amass L. [Two-year experience with buprenorphine-naloxone \(Suboxone\) for maintenance treatment of opioid dependence within a private practice setting](#). *J Addict Med*. 2014;1(2):104-110.
- Fiore MC, Jaén CR, Baker TB, et al. [Treating Tobacco Use and Dependence: 2008 Update](#). Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
- Fishbain DA, Cole B, Lewis J, et al. [What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review](#). *Pain Med*. 2008;9(4):444-459.
- Fishman MJ, Mee-Lee D, Schulman GD, et al. [Supplement to the ASAM Patient Placement Criteria on the Management of Alcohol Use Disorders](#). Baltimore, MD: Lippincott, Williams & Wilkins, Inc; 2010.

- Fishman MJ, Wu LT, Woody GE. [Buprenorphine for Prescription Opioid Addiction in a Patient With Depression and Alcohol Dependence](#). *Am J Psychiatry*. 2011;168(7):675-679.
- Food and Drug Administration (FDA). [Appropriate Use Checklist](#). <http://btodrems.com/>. 2013.
- Food and Drug Administration (FDA). [Buprenorphine Drug Label](#). 2010.
- Food and Drug Administration (FDA). [Buprenorphine-containing Transmucosal products for Opioid Dependence \(BTOD\) Risk Evaluation and Mitigation Strategy \(REMS\)](#). 2013.
- Food and Drug Administration (FDA). [Physician Information: Answers to Frequently Asked Questions](#). 2010.
- Frenk SM, Porter KS, Paulozzi LJ. [Prescription opioid analgesic use among adults: United States, 1999-2012](#). NCHS Data Brief. 2015;189.
- FSMB. [Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office](#). FSMB Website. 2013.
- Fudin J. [A Brief Review of Buprenorphine Products](#). March 2016.
- Gallagher C. [What Waivered Physicians Need to Understand About DEA Requirements](#). 2010.
- Gerteis M. *Through the Patient's Eyes: Understanding and Promoting Patient-Centered Care*. Vol 1st ed. San Francisco: Jossey-Bass; 1993.
- Glasper A, Reed LJ, de Wet CJ, et al. [Induction of patients with moderately severe methadone dependence onto buprenorphine](#). *Addict Biol*. 2005;10(2):149-155.
- Gourlay D, Heit HA, Caplan YH. [Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care](#). Johns Hopkins Med. 2012;5.
- Gourlay D. [Urine Drug Testing in Chronic Pain: A Patient Centered Approach \(AMA\) \[webinar\]](#). 2013.
- Gruber VA, McCance-Katz EF. [Methadone, buprenorphine, and street drug interactions with antiretroviral medications](#). *Curr HIV/AIDS Rep*. 2010;7(3):156-160.
- Gudin JA, Mogali S, Jones JD. [Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use](#). *Postgrad Med*. 2013;125(4):115-130.
- Gunderson E. [Models of Buprenorphine Induction](#). PCSSMAT Train. 2014.
- Guo AY, Ma JD, Best BM, et al. [Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine](#). *J Anal Toxicol*. 2013;37(9):636-641.
- Gyarmathy VA, Neaigus A, Miller M, et al. [Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users](#). *J Acquir Immune Defic Syndr*. 2002;30(4):448-456.
- Hagan H, Pouget ER, Des Jarlais DC. [A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs](#). *J Infect Dis*. 2011;204:74-83.
- Hale D, Viner R. [Trends in the prevalence of multiple substance use in adolescents in England, 1998-2009](#). *J of Public Health, Oxford*. 2013;35(3):367-374.
- Harned M, Sloan P. [Safety concerns with long-term opioid use](#). *Expert Opin Drug Saf*. 2016;15(7):955-962.
- Hashim MJ. [Patient-Centered Communication: Basic Skills](#). *Am Fam Physician*. 2017;95(1):39-34.
- Hasin D, Liu XH, Nunes E, et al. [Effects of major depression on remission and relapse of substance dependence](#). *Arch Gen Psychiatry*. 2002;59:375-380.
- Hedegaard H, Warner M, Minino A. [Drug overdose deaths in the United States, 1999-2016](#). December 2017.

- Heit HA, Gourlay DL. [Urine drug testing in pain medicine](#). J Pain Symptom Manage. 2004;27:260-267.
- Henry JA. [Metabolic consequences of drug misuse](#). Br J Anaesth. 2000;85(1):136-142.
- Herve S, Riachi G, Noblet C, et al. [Acute hepatitis due to buprenorphine administration](#). Eur J Gastroenterol Hepatol. 2004;16(10):1033-1037.
- Hesse M. [The ASRS-6 Has Two Latent Factors: Attention Deficit and Hyperactivity](#). J Atten Disord. 2011;17(3):203-207.
- HHS. [HHS announces new actions to combat opioid epidemic](#). HHS.gov. July 2016.
- Hopfer CJ, Khuri E, Crowley TJ, et al. [Adolescent heroin use: a review of the descriptive and treatment literature](#). J Subst Abuse Treat. 2002;23(3):231-237.
- Hubbard RL, Craddock SG, Anderson J. [Overview of 5-year followup outcomes in the drug abuse treatment outcome studies \(DATOS\)](#). 2003.
- Huestis MA. [High-dose buprenorphine in humans](#). In: Kintz P, Marquet P, Eds. Buprenorphine Therapy of Opiate Addiction. Vol Totowa, NJ: Humana Press, Inc; 2002.
- Indivior Inc. [Suboxone Highlights of Prescribing Information](#). <http://www.suboxone.com/>. December 2016.
- Institute of Medicine (IOM). [Crossing The Quality Chasm: A New Health System For The 21st Century](#). IOM. 2001.
- Irwin RS, Rippe JM. [Irwin and Rippe's Intensive Care Medicine](#). Lippincott Williams & Wilkins; 2012.
- Johanson CE, Arfken CL, DiMenza S, et al. [Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians](#). Drug Alcohol Depend. 2012;120(1-3):190-195.
- Johnson RE, Strain EC, Amass L. [Buprenorphine: how to use it right](#). Drug Alcohol Depend. 2003;70(suppl 2):S59-S77.
- Jones CM, Logan J, Gladden M, et al. [Vital signs: Demographic and substance use trends among heroin users — United States, 2002-2013](#). CDC Morb Mortal Wkly Rep. 2015;64(26):719-725.
- Jones HE, Fischer G, Heil SH. [Maternal Opioid Treatment: Human Experimental Research \(MOTHER\) - approach, issues and lessons learned](#). Addiction. 2012;107:28-35.
- Jones HE, Kaltenbach K, Heil SH, et al. [Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure](#). N Engl J Med. 2010;363:2320-2331.
- Jones HE. [Treating opioid use disorders during pregnancy: historical, current, and future directions](#). Subst Abus. 2013;34(2):89-91.
- Joseph AM, Willenbring ML, Nugent SM, et al. [A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment](#). J Stud Alcohol. 2004;65(6):681-691.
- Jung O, Haack HS, Buettner M. [Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection?](#). BMC Nephrol. 2012;13.
- Kahan M, Srivastava A, Ordean A, et al. [Buprenorphine: new treatment of opioid addiction in primary care](#). Can Fam Physician. 2011;57(3):281-289.
- Kakko J, Svanborg KD, Kreek MJ, et al. [1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial](#). Lancet. 2003;361(9358):662-668.

- Kalman D, Morissette SB, George TP. [Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders](#). *Am J Addict*. 2005;14(2):106-123.
- Kao Ming-Chih, Zheng Patricia, Mackey Sean, et al. [Trends in Benzodiazepine Prescription and Co-Prescription with Opioids in the United States, 2002--2009](#). AAPM Annual Meeting. July 2014.
- Kaul P, Coupey SM. [Clinical evaluation of substance abuse](#). *Pediatr Rev*. 2002;23(3):85-94.
- Kidorf M, Disney ER, King VL, et al. [Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program](#). *Drug Alcohol Depend*. 2004;74(2):115-122.
- Kissin W, McLeod C, Sonnefeld J, et al. [Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence](#). *J Addict Dis*. 2006;25(4):91-103.
- Kleber H, Weiss R, Anton R, et al. [Practice guideline for the treatment of patients with substance use disorders](#). Vol 3rd edition. American Psychiatric Association; 2010.
- Klimas Jan, Field Catherine-Anne, Cullen Walter, et al. [Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users: Cochrane Review](#). *Syst Rev*. 2013;2.
- Knight JR, Shrier LA, Bravender TD, et al. [A new brief screen for adolescent substance abuse](#). *Arch Pediatr Adolesc Med*. 1999;153(6):591-596.
- Kosten TR, George TP. [The neurobiology of opioid addiction: implications for treatment](#). *NIDA Sci Pract Perspect*. 2002;1(1):13-20.
- Kraus ML, Alford DP, Kotz MM, et al. [Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction](#). *J Addict Med*. 2011;5(4):254-263.
- Labelle CT, Han SC, Bergeron A, et al. [Office-Based Opioid Treatment with Buprenorphine \(OBOT-B\): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers](#). *J Subst Abuse Treat*. 2015;15.
- Lange CM, Jacobson IM, Rice CM. [Emerging therapies for the treatment of hepatitis C](#). *EMBO Mol Med*. 2014;6:4-15.
- Larance B, Lintzeris N, Dietze P, et al. [The diversion and injection of a buprenorphine-naloxone soluble film formulation](#). *Drug Alcohol Depend*. 2014;136:21-27.
- Lavonas EJ, Banner W, Bradt P, et al. [Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children](#). *J Pediatr*. 2013;163(5):1377-1383.
- Lee JD, Friedmann PD, Kinlock TW, et al. [Extended-release naltrexone to prevent opioid relapse in criminal justice offenders](#). *N Engl J Med*. 2016;374:1232-1242.
- Lee JD, Grossman E, DiRocco D, et al. [Home Buprenorphine/Naloxone Induction in Primary Care](#). *J Gen Intern Med*. 2009;24(2):226-232.
- Leger DL. [Study: heroin use is higher than a decade ago](#). *USA Today*. 2015.
- Lemon SC, Friedmann PD, Stein MD. [The impact of smoking cessation on drug abuse treatment outcome](#). *Addict Behav*. 2003;28(7):1323-1331.
- Levy S, Vaughan BL, Angulo M, et al. [Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program](#). *J Adolesc Health*. 2007;40(5):477-482.



- Ling W, Casadonte P, Bigelow G. [Buprenorphine Implants for Treatment of Opioid Dependence](#). JAMA. 2010;304(14):1576-1583.
- Ling W, Hillhouse M, Domier C, et al. [Buprenorphine tapering schedule and illicit opioid use](#). Addiction. 2009;104(2):256-265.
- Ling W. Prescription Drug Abuse. Western Conference on Addiction. November 13, 2005. Universal City, CA.
- Lintzeris N, Clark N, Muhleisen P, et al. [National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence](#). 2001.
- Lofwall M. [Minimizing the Risks of Buprenorphine Diversion and Misuse from Office-Based Treatment](#). 2011.
- Lofwall MR, Havens JR. [Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine](#). Drug Alcohol Depen. 2012;Jun 13 [Epub ahead of print].
- Lofwall MR, Walsh SL. [A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world](#). J Addict Med. 2014;8(5):315-326.
- Lowes R. [e-Prescribing Controlled Substances Now Legal Nationwide](#). MedScape. 2015.
- Lundahl B, Moleni T, Burke BL, et al. [Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials](#). 93. 2013;2:157-168.
- Madras BK, Wilson MC, Avula D, et al. [Screening, brief interventions, referral to treatment \(SBIRT\) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months](#). Drug Alcohol Depend. 2010;99(1-3):280-295.
- Magill M, Stout RL, Apodaca TR. [Therapist focus on ambivalence and commitment: a longitudinal analysis of motivational interviewing treatment ingredients](#). Psychol Addict Behav. 2013;27:754-762.
- Manchikanti L, Manchukonda R, Damron KS. [Does adherence monitoring reduce controlled substance abuse in chronic pain patients?](#). Pain Physician. 2006;9(1):57-60.
- Mannelli P, Peindl KS, Lee T. [Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives](#). Curr Drug Abuse Rev. 2012;5(1):52-63.
- Manubay JM, Muchow C, Sullivan MA. [Prescription drug abuse: epidemiology, regulatory issues, chronic pain management with narcotic analgesics](#). Prim Care. 2011;38(1):71-90, vi.
- Marshal Michael P, Molina Brooke SG, Pelham William E. [Childhood ADHD and Adolescent Substance Use: An Examination of Deviant Peer Group Affiliation as a Risk Factor](#). Psychol Addict Behav J Soc Psychol Addict Behav. 2003;17(4):293-302. doi:10.1037/0893-164X.17.4.293.
- Marshall PS. [Physical Functional Ability Questionnaire \(FAQ5\)](#). In: In: Assessment and Management of Chronic Pain. Vol 14. 5th edition. Institute for Clinical Systems Improvement; 2011:Appendix C:99.
- Martin J. [Adherence, Diversion and Misuse of Sublingual Buprenorphine](#). updated 2014 2009.
- Martin J. [PCSS-MAT Guidance: Pregnancy and buprenorphine treatment](#). Physicians' Clinical Support System for Medication Assisted Treatment (PCSS-MAT). 2006.
- Martin J. Personal Communication Re: Number of Patients Maintained on Buprenorphine. 2011.
- Martin T, Rocque M. [Accidental and Non-Accidental Ingestion of Methadone and Buprenorphine in Childhood: A Single Center Experience, 1999-2009](#). Curr Drug Saf. 2009;6:12-16.

- Martins SS, Keyes KM, Storr CL. [Pathways between non-medical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions](#). *Drug Alcohol Depend*. 2009;103:16-24.
- Matson SC, Hobson G, Abdel-Rasoul M, et al. A Retrospective Study of Retention of Opioid-Dependent Adolescents and Young Adults in an Outpatient Buprenorphine/Naloxone Clinic. *Addict Behav*. 2014;8(3):176-182.
- Mattick RP, Breen C, Kimber J. [Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence](#). *Cochrane Libr*. 2014.
- Maxwell JC, McCance-Katz EF. [Indicators of buprenorphine and methadone use and abuse: what do we know?](#). *Am J Addict*. 2010;19(1):73-88.
- McCance-Katz EF, Moody DE, Morse GD, et al. [Interaction between buprenorphine and atazanavir or atazanavir/ritonavir](#). *Drug Alcohol Depend*. 2007;91(2-3):269-278.
- McCance-Katz EF. [Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid-Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents](#). *Clin Infect Dis*. 2005;41(suppl 1):S89-95.
- McCarthy JJ, Leamon MH, Parr MS, et al. [High-dose maintenance in pregnancy: maternal and neonatal outcomes](#). *Am J Obstet Gynecol*. 2005;193(3 Pt 1):606-610.
- McClellan AT, McKay JR. [Components of successful addiction treatment](#). In: N: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. *Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003:3.
- McNicholas LF. [Buprenorphine: Induction, Dosing and Related Issues](#). American Psychiatric Association Sponsored Webinar; 2011.
- Mdege ND, Lang J. [Screening instruments for detecting illicit drug use abuse that could be useful in general hospital wards: a systematic review](#). *Addict Behav*. 2011;36:1111-1119.
- Medscape. [Sublocade \(buprenorphine, long-acting injection\) dosing, indications, interactions, adverse effects, and more](#). 2018.
- Mee-Lee D. [The ASAM Criteria](#). Vol 3rd edition. ASAM; 2013.
- Melemis SM. [Relapse prevention and the five rules of recovery](#). *Yale J Biol Med*. 2015;88:3.
- Mendelson J, Jones RT. [Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?](#). *Drug Alcohol Depend*. 2003;70(2S):S29-S37.
- Miller William R, Rollnick Stephen. [Motivational Interviewing: Helping People Change](#), 3rd Edition. Vol 3rd edition. New York, NY: The Guilford Press; 2012.
- Miller WR, Rollnick S. [An Overview of Motivational Interviewing](#). 2011.
- Minozzi S, Amato L, Davoli M. [Maintenance treatments for opiate dependent adolescent](#). *Cochrane Database Syst Rev*. 2009;15(2):CD007210.
- Mintzer IL, Eisenberg M, Terra M, et al. [Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings](#). *Ann Fam Med*. 2007;5(2):146-150.
- Monte AA, Mandell T, Wilford BB, et al. [Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence](#). *J of Addictive Diseases*. 2009;28:226-231.

- Monto A, Currie S, Wright TL. [Liver disease in injection drug users with hepatitis C, with and without HIV coinfection](#). J Addict Dis. 2008;27(2):49-59.
- Moore BA, Fiellin DA, Barry DT, et al. [Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients](#). J Gen Intern Med. 2007;22:527-530.
- Moos RH, Moos BS, Finney JW. [Predictors of deterioration among patients with substance-use disorders](#). J Clin Psychol. 2001;57(12):1403-1419.
- Morasco BJ, Cavanagh R, Gritzner S, et al. [Care management practices for chronic pain in veterans prescribed high doses of opioid medications](#). Farm Pract. 2013;6:671-678.
- Nasser AF, Heidbreder C, Liu Y, et al. [Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment \(Child-Pugh classes A, B, and C\), in hepatitis C virus-seropositive subjects, and in healthy volunteers](#). Clin Pharmacokinet. 2015;54(8):837-849.
- National Center for Complementary and Integrative Health. [NIH Analysis Shows Americans are in Pain](#). Natl Inst Health. 2015.
- National Drug Intelligence Center (NDIC). [Intelligence Bulletin: Buprenorphine: Potential for Abuse](#). 2004.
- National Institute on Drug Abuse. [Linked Epidemics: Drug Abuse and HIV/AIDS](#). 2005.
- NCCHC. [Substance Use Disorder Treatment for Adults and Adolescents](#). October 2016.
- Neaigus A, Miller M, Gyarmathy VA, et al. [HIV heterosexual sexual risk from injecting drug users among HIV-seronegative noninjecting heroin users](#). Subst Use Misuse. 2011;46(2-3):208-217.
- NIAAA. [Alcohol Facts and Statistics](#). NIAAA. 2015.
- NIDA. [Principles of drug addiction treatment: A research-based guide \(Third Edition\)](#). December 2012.
- NIDA. [Screening for drug use in general medical settings](#). <http://www.drugabuse.gov/>. 2012.
- Nielsen S, Hillhouse M, Thomas C. [A comparison of buprenorphine taper outcomes between prescription opioid and heroin users](#). J Addict Med. 2013;7(1):33-38.
- NIH. [National Trends](#). 2014.
- O'Connor AB, Collett A, Alto WA, et al. [Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy](#). Journal of Midwifery Women's Health. 2013;58(4):383-388.
- Office of National Drug Control Policy. [Medication-Assisted Treatment for Opioid Addiction](#). 2012.
- Öhlin L, Fridell M, Nyhlén A. [Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years](#). BMC Psychiatry. 2015;15(56).
- Oreskovich MR, Saxon AJ, Ellis ML, et al. [A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin](#). Drug Alcohol Depend. 2005;77(1):71-79.
- Orexo US Inc. [Zubsolv prescribing information](#). 2013.
- Pade PA, Cardon KE, Hoffman RM, et al. [Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model](#). J Subst Abuse Treat. 2012;43(4):446-450.
- Pajusco B, Chiamulera C, Quaglio G, et al. [Tobacco Addiction and Smoking Status in Heroin Addicts under Methadone vs. Buprenorphine Therapy](#). Int J Environ Res Public Health. 2012;9(3):932-942.

- Pani PP, Vacca R, Troqu E, et al. [Pharmacological treatment for depression during opioid agonist treatment for opioid dependence](#). *Cochrane Database Syst Rev*. 2010;8(9):CD008373.
- Papastavrou E, Farmakas A, Karayiannis G, et al. [Co morbidity of Post-Traumatic-Stress Disorders and Substance Use Disorder](#). *Health Science Journal*. *Health Sci J*. 2011;5(2):107-117.
- Passik S. [Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation](#). *J Pain Palliat Care Pharmacother*. 2006;20(2):5-13.
- Paulozzi LJ, Baldwin G. [CDC Grand Rounds: Prescription Drug Overdoses — a U.S. Epidemic](#). *CDC Morb Mortal Wkly Rep*. 2012;61(01):10-13.
- PCSS. [Vivitrol: How important is this piece of the treatment puzzle?](#). 2015.
- PCSS. [XR-Naltrexone: A step-by-step guide](#). 2017.
- Perneger TV, Klag MJ, Whelton PK. [Recreational drug use: a neglected risk factor for end-stage renal disease](#). *Am J Kidney Dis*. 2001;38(1):49-56.
- Pickett M, Rogers PD, Cavanaugh Jr RM. [Screening for alcohol, tobacco, and drug use in children and adolescents](#). In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. *Principles of Addiction Medicine*. Vol Third Edition. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
- Potter JS, Marino EN, Hillhouse MP. [Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies \(START\)](#). *J Stud Alcohol Drugs*. 2013;74(4):605-613.
- Prochaska JJ, Delucchi K, Hall SM. [A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery](#). *J Consult Clin Psychol*. 2004;76(6):1144-1156.
- Purdue Pharma. [Butrans™ CIII \(buprenorphine\) Transdermal System](#). Butrans Website. 2010.
- Reckitt Benckiser Pharmaceuticals Inc. [Buprenex injectable - RX only - Schedule III](#). 2007.
- Reckitt Benckiser Pharmaceuticals Inc. [SUBOXONE \(buprenorphine hydrochloride, naloxone hydrochloride\) film, soluble \[Reckitt Benckiser Pharmaceuticals Inc\]](#). DailyMed. 2014.
- Reckitt Benckiser Pharmaceuticals Inc. [Suboxone Prescribing Information](#). 2014.
- Reid MS, Mickalian JD, Delucchi KL, et al. [An acute dose of nicotine enhances cue-induced cocaine craving](#). *Drug Alcohol Depend*. 1998;49(2):95-104.
- Reid MS, Selzer J, Rotrosen J. [Smoking Cessation treatment at Substance Abuse Rehabilitation Programs](#). *Northeast ATTC Newsl*. 2006;5(2):2-5.
- Reisfield Gary M, Maschke Karen J. [Urine Drug Testing in Long-Term Opioid Therapy: Ethical Considerations](#). *Clin J Pain*. 2014;30(8):679-684. doi:10.1097/01.ajp.0000435448.34761.c9.
- Renner Britta, Kwon Sunkyo, Yang Byung-Hwan, et al. [Social-Cognitive Predictors of Dietary Behaviors in South Korean Men and Women](#). *Int J Behav Med*. 2008;15(1):4-13. doi:10.1080/10705500701783785.
- Renner J, Lavounis P. [Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence](#). Arlington, VA: American Psychiatric Publishing; 2011.
- Renner J, Saxon A, Levounis P. [Buprenorphine Update and Evolving Standards of Care](#). IPS: The Mental Health Services Conference. October 2015. New York City.
- Reuter N. Personal Communication via E-Mail Re: Buprenorphine Waivered Physicians. 2011.

- Richert Torkel, Johnson Björn. [Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden](#). *Harm Reduct J*. 2015;12. doi:10.1186/s12954-015-0037-2.
- Roll David, Spottswood Margaret, Huang Hsiang. [Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment](#). *J Am Board Fam Med JABFM*. 2015;28(5):676-677. doi:10.3122/jabfm.2015.05.150017.
- Romano G, Barbera N, Spadaro G, et al. [Determination of drugs of abuse in hair: evaluation of external heroin contamination and risk of false positives](#). *Forensic Sci Int*. 2003;131(2-3):98-102.
- Rondinelli AJ, Ouellet LJ, Strathdee A, et al. [Young adult injection drug users in the United States continue to practice HIV risk behaviors](#). *Drug Alcohol Depend*. 2009;104(1-2):167-174.
- Rosenthal RN, Lofwall MR, Kim S, et al. [Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. A randomized clinical trial](#). *JAMA*. 2016;316:282-290.
- Roxane Laboratories. [Buprenorphine and naloxone sublingual tablets: Full prescribing information](#). DailyMed. 2016.
- Rudd Rose A. [Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015](#). *MMWR Morb Mortal Wkly Rep*. 2016;65. doi:10.15585/mmwr.mm65051e1.
- Rx List. [Suboxone](#). Rx List Website. 2014.
- RxList. [Ativan \(Lorazepam\): Side Effects, Interactions, Warning, Dosage & Uses](#). RxList. 2017.
- RxList. [Diazepam \(Diazepam Tablets\): Side Effects, Interactions, Warning, Dosage & Uses](#). RxList. 2017.
- RxList. [Oxazepam \(Oxazepam Tablets\): Side Effects, Interactions, Warning, Dosage & Uses](#). RxList. 2017.
- Saber-Tehrani AS, Bruce RD, Altice FL. [Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence](#). *Am J Drug Alcohol Abuse*. 2011;37(1):1-11.
- Salsitz EA, Wunsch MJ. [PCSS-B Guidance on Drug Enforcement Administration Requirements for Prescribers and Dispensers of Buprenorphine and Buprenorphine/Naloxone](#). 2010.
- SAMHSA Press Office. [Sharp rise in buprenorphine-related emergency department visits from 2005 to 2010](#). 2013.
- SAMHSA. [An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence](#). SAMHSA Advis. 2012;HHS Publication No. (SMA) 12-4682:1-8.
- SAMHSA. [Clinical Drug Testing in Primary Care](#). SAMHSA Website. 2012.
- SAMHSA. [Decisions in Recovery. Treatment for Opioid Use Disorder](#). 2017.
- SAMHSA. [Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health](#). SAMHSA.gov. 2017.
- SAMHSA. [Methadone](#). SAMHSA.gov. 2015.
- SAMHSA. [Number of DATA Certified Physicians](#). SAMHSA.gov. 2015.
- SAMHSA. [Physician and Program Data](#). SAMHSA.gov. 2018.
- SAMHSA. [Protracted withdrawal](#). SAMHSA Advis. 2010;9(1).
- SAMHSA. [SAMHSA opioid overdose prevention toolkit](#). 2014.

- SAMHSA. [Screening, Brief Intervention, and Referral to Treatment \(SBIRT\)](#). 2014.
- SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
- SAMHSA. [Substance Abuse Confidentiality Regulations](#). 2015.
- SAMHSA. [Substance Use Disorders](#). SAMHSA Website. 2014.
- SAMHSA. [Tobacco Use Cessation During Substance Abuse Treatment Counseling](#). SAMHSA Advis. 2011;10(2):1-8.
- SAMHSA. [Treatment of Adolescents With Substance Use Disorders](#). Treatment Improvement Protocol Series, No. 32. Rockville, Md: Center For Substance Abuse Treatment; 1999.
- SAMHSA. [Treatments for Substance Use Disorders](#). 2015.
- SAMHSA. [Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians](#). 2001.
- SAMHSA/CSAT. [Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction](#). 2004.
- SAMHSA/CSAT. [Confidentiality of Patient Records for Alcohol and Other Drug Treatment](#). Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
- SAMHSA/CSAT. [Intensive Outpatient Treatment for Alcohol and Other Drug Abuse](#). Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
- SAMHSA/CSAT. [Treatment for Alcohol and Other Drug Abuse: Opportunities for Coordination](#). Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
- SAMSHA. [National Survey of Substance Abuse Treatment Services \(N-SSATS\): 2014](#). ; 2016.
- SAMSHA. [Treatment Episode Data Set \(TEDS\): 2000-2010. National Admissions to Substance Abuse Treatment Services](#). 2012.
- Sansone RA, Whitecar P, Wiederman MW. [The prevalence of borderline personality among buprenorphine patients](#). Int J Psychiatry Med. 2008;38(2):217-226.
- Savage SD, Kirsh KL, Passik SD. [Challenges in using opioids to treat pain in persons with substance use disorders](#). Addict Sci Clin Pract. 2008;4(2):4-25.
- Saxon AJ, Ling W, Hillhouse M, et al. [Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial](#). Drug Alcohol Depend. 2013;128:71-76.
- Schoener EP, Hopper JA, Pierre JD. [Injection drug use in North America](#). Infect Dis Clin North Am. 2002;16(3):535-551.
- Schulz JE, Parran T Jr. Principles of Identification and Intervention. In: Principles of Addiction Medicine. Vol 2nd ed. Chevy Chase, Md.: American Society of Addiction Medicine; 1998:250-251.
- Seal KH, Shi Y, Cohen G. [Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan](#). JAMA. 2012;307:940-947.
- Sees KL, Clark HW. [When to begin smoking cessation in substance abusers](#). J Subst Abuse Treat. 1993;10(2):189-195.
- Shoptaw S, Rotheram-Fuller E, Yang X, et al. [Smoking cessation in methadone maintenance](#). Addiction. 2002;97(10):1317-1328.

- Smith PC, Schmidt SM, Allensworth-Davies D, et al. [A single-question screening test for drug use in primary care](#). Arch Intern Med. 2010;170(13):1155-1160.
- Sokol Randi, Albanese Chiara, Chaponis Deviney, et al. [Why Use Group Visits for Opioid Use Disorder Treatment in Primary Care? A Patient-Centered Qualitative Study..](#) Subst Abuse. 2018;39(1):52-58. doi:10.1080/08897077.2017.1356792.
- Sontag D. [Addiction Treatment With a Dark Side](#). N Y Times. 2013.
- Soyka M. [Buprenorphine and buprenorphine/naloxone intoxication in children -- How strong is the risk?.](#) Curr Drug Abuse Rev. 2013;6(1):63-70.
- Stanhope TJ, Gill LA, Rose C. [Chronic opioid use during pregnancy: maternal and fetal implications](#). Clin Perinatol. 2013;40(3):337-350.
- Stanton A, McLoed C, Luckey B, et al. [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program](#). 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
- Stein DJ, Iper JC, Seedat S. [Pharmacotherapy for post traumatic stress disorder \(PTSD\)](#). Cochrane Database Syst Rev. 2006;1:CD002795.
- Stephenson DK, SAM Committee on Treatment of Opioid Dependence. [Draft Guidelines for Physicians Working in California Opioid Treatment Programs](#). 2008.
- Sterling S, Chi F, Hinman A. [Integrating Care for People With Co-Occurring Alcohol and Other Drug, Medical, and Mental Health Conditions](#). Alcohol Res Health. 2011;33(4):338-349.
- Stewart DG, Brown SA. [Withdrawal and dependency symptoms among adolescent alcohol and drug abusers](#). Addiction. 1995;90(5):627-635.
- Stine SM, Greenwald MK, Kosten TR. [Pharmacologic interventions for opioid addiction](#). In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol Third Edition. Chevy Chase, Md; 2003.
- Strain EC, Moody DE, Stoller KE, et al. [Relative bioavailability of different buprenorphine formulations under chronic dosing conditions](#). Drug Alcohol Depend. 2004;74(1):37-43.
- Strain EC. [Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients](#). Clin J Pain. 2002;18(4 Suppl)(S14-27).
- Sublocade. [Medication Guide Sublocade \(buprenorphine extended-release\) injection, for subcutaneous use \(CIII\)](#). November 2017.
- Subramaniam G, Levy S. [PCSS-MAT Guidance: Treatment of opioid dependent adolescents and young adults using sublingual buprenorphine](#). 2010.
- Subramaniam GA, Fishman MJ, Woody G. [Treatment of opioid-dependent adolescents and young adults with buprenorphine](#). Curr Psychiatry Rep. 2009;11(5):360-363.
- Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT). [A Guide to Substance Abuse Services for Primary Care Clinicians](#). Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2008.
- Substance Abuse and Mental Health Services Administration (SAMHSA). [About Buprenorphine Therapy](#). 2011.
- Substance Abuse and Mental Health Services Administration (SAMHSA). [Results from the 2012 national survey on drug use and health: summary of national findings](#). U.S. Department of Health and Human Services; 2013.

- Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). [Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health](#). Washington (DC): US Department of Health and Human Services; 2016.
- Substance Abuse and Mental Health Services Administration. [Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings](#). ; 2014.
- Sullivan JT, Sykora K, Schneiderman J, et al. [Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale \(CIWA-Ar\)](#). Br J Addict. 1989;84(11):1353-1357.
- Sullivan L, Fiellin D. [Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice](#). Ann Intern Med. 2008;148(9):662-670.
- Sullivan M, Martin J (original author). [New Information on Buprenorphine Treatment During Pregnancy](#). 2014.
- Sullivan MA, Covey LS. [Current perspectives on smoking cessation among substance abusers](#). Curr Psychiatry Rep. 2002;4(5):388-396.
- Sullivan MA, Gordon AJ. [MAT training: Provider's clinical support system for medication assisted treatment](#). 2013.
- Szabo L. [Addiction treatment hard to find, even as overdose deaths soar](#). USA Today. 2015.
- Tamm L, Trello-Rishel K, Riggs P, et al. [Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder](#). Subst Abuse Treat. 2013;44(2):224-230.
- Taylor FB, Martin P, Thompson C, et al. [Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study](#). Biol Psychiatry. 2008;63(6):629-632.
- Thomas CP, Fullerton CA, Kim M, et al. [Medication-assisted treatment with buprenorphine: assessing the evidence](#). Psychiatr Serv. 2014;65(2):158-170.
- Tofighi Babak, Grossman Ellie, Buirkle Emily, McNeely Jennifer, Gourevitch Marc, Lee Joshua D. [Mobile Phone Use Patterns and Preferences in Safety Net Office-Based Buprenorphine Patients..](#) J Addict Med. 2015;9(3):217-221. doi:10.1097/ADM.000000000000121.
- Tolia VN, Patrick SW, Bennett MM, et al. [Increasing incidence of the neonatal abstinence syndrome in U.S. Neonatal ICUs](#). NEJM. 2015;372:2118-2126.
- Trachtenberg AI, Fleming MF. [Diagnosis and Treatment of Drug Abuse in Family Practice](#). 1994.
- TransMed. [CLIA Screen In-Vitro \(CSI\) 12-Panel Drug Test Screening Cup CLIA Waived](#). TransMed Drug Test Lab Supplies. 2018.
- Trémeau F, Darreya A, Staner L, et al. [Suicidality in opioid-dependent subjects](#). Am J Addict. 2008;17(3):187-194.
- Tzschentke Thomas M. [Behavioral Pharmacology of Buprenorphine, with a Focus on Preclinical Models of Reward and Addiction](#). Psychopharmacology (Berl). 2002;161(1):1-16. doi:10.1007/s00213-002-1003-8.
- U.S. Census Bureau. [2012 Statistical Abstract of the United States](#). Census.gov. 2012.
- U.S. Department of Health and Human Services. [Addressing prescription drug abuse in the United States](#). 2013.
- U.S. Drug Enforcement Administration (DEA), Office of Diversion Control. [National Forensic Laboratory Information System: Year 2009 Annual Report](#). National Forensic Library Information System Annual Report; 2010.



- U.S. House of Representatives. [Comprehensive Addiction and Recovery Act of 2016](#). docs.house.gov. 2016.
- U.S. Preventive Services Task Force. [Screening for Illicit Drug Use](#). 2008.
- UMBCtube. [SBIRT: Screen for Substance Use - Negative Screen](#). UMBCTube; 2011.
- US Department of Justice. [Title 21 Code of Federal Regulations: PART 1311 —REQUIREMENTS FOR ELECTRONIC ORDERS AND PRESCRIPTIONS](#). 2010.
- USDHHS. [Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements](#). 2016.
- USPSTF. [Draft Update Summary: Unhealthy Alcohol Use in Adolescents and Adults, Including Pregnant Women: Screening and Behavioral Counseling Interventions - US Preventive Services Task Force](#). August 2016.
- VA/DoD. [VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders](#). VA/DoD. 2015.
- Verheul R. [Co-morbidity of personality disorders in individuals with substance use disorders](#). Eur Psychiatry. 2001;16(5):274-282.
- Vivolo-Kantor Alana M. [Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses — United States, July 2016–September 2017](#). MMWR Morb Mortal Wkly Rep. 2018;67. doi:10.15585/mmwr.mm6709e1.
- Vivus, Inc. [Highlights of Prescribing Information](#). FDA.org. 2014.
- Volkow N. [NIDA-supported science leads to first FDA-approved medication for opioid withdrawal](#). NIDA. 2018.
- Waknine Y. [FDA Approves 7-Day Buprenorphine Pain Patch](#). 2010.
- Walden Greg. [H.R.6 - 115th Congress \(2017-2018\): SUPPORT for Patients and Communities Act](#). October 2018.
- Walden Greg. [Text - H.R.6 - 115th Congress \(2017-2018\): SUPPORT for Patients and Communities Act](#). October 2018.
- Walsh SL. [Clinically Relevant Pharmacology of Buprenorphine](#). 2009.
- Wang J, Christo PJ. [The influence of prescription monitoring programs on chronic pain management](#). Pain Physician. 2009;12:507-515.
- Warden Diane, Riggs Paula D, Min Sung-Joon, et al. [Major depression and treatment response in adolescents with ADHD and substance use disorder](#). Drug Alcohol Depend. 2011;120(1-3):214-219.
- Warner M, Chen LH, Makuc DM. [Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006](#). 2009.
- Warner M, Hedegaard H, Chen LH. [Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012](#). 2014.
- Wartenberg A. [Management of Buprenorphine Side Effects](#). 2013.
- Washington State Agency Medical Directors' Group (AMDG). [Interagency Guideline on Prescribing Opioids for Pain](#). June 2015.
- Weiss RD, Potter JS, Fiellin DA. [Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence](#). Arch Gen Psychiatry. 2012;68(12):1238-1246.
- Weiss RD, Potter JS, Griffin ML, et al. [Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study](#). Drug Alcohol Depend. 2015.

- Weiss Roger D, Potter Jennifer S, Copersino Marc L, et al. Conducting Clinical Research with Prescription Opioid Dependence: Defining the Population. *Am J Addict.* 2010;19(2):141-146. doi:10.1111/j.1521-0391.2009.00017.x.
- Wish ED, Artigiani D, Billing A, et al. [The emerging buprenorphine epidemic in the United States.](#) *J Addict Dis.* 2012;31(1):3-7.
- Woody G, Poole S, Subramaniam G, et al. [Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.](#) *AMA.* 2008;300(17):2003-2011.
- Wu LT, Woody GE, Yang C, et al. [Subtypes of nonmedical opioid users: results from the National Epidemiologic Survey on Alcohol and Related Conditions.](#) *Drug Alcohol Depend.* 2010;112:69-80.
- Xi ZX, Stein EA. [GABAergic mechanisms of opiate reinforcement.](#) *Alcohol Alcohol.* 2002;37(5):485-494.
- Yokell MA, Zaller ND, Green TC, et al. [Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.](#) *Curr Drug Abuse Rev.* 2011;4:28-41.
- Zacny J, Bigelow G, Compton P, et al. [College on Problems of Drug Dependence task force on prescription opioid non-medical use and abuse: position statement.](#) *Drug Alcohol Depend.* 2003;69(3):215-232.
- Zubkoff L, Shiner B, Watts BV. [Staff Perceptions of Substance Use Disorder Treatment in VA Primary Care-Mental Health Integrated Clinics.](#) *J Subst Abuse Treat.* 2016;70:44-49.